Key facts
- It has raised $116.0M across 2 recorded rounds; the latest was Early Stage VC (Series B) ($116.0M) in Jan 2022.
- 2 institutional filers report fund marks on Korro Bio across 9 filings.
- Korro Bio has filed 1 Form D with the SEC, most recently Jun 2019 ($4.0M sold to 1 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for Korro Bio
Create free account
No card required
Funding rounds
2 roundsJan 2022Early Stage VC (Series B)$116.0M▮
About Korro Bio
- Industry
- Drug Discovery
PA Mark — not yet priced
Korro Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Korro Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
2 filers · latest May 20262 SEC-registered funds reported 9 fair-value marks on Korro Bio between Apr 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.